Intelligent Investor

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.065 0.001 (1.56%)

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$13 Entitlement Offer - Offer Booklet 24 Apr 2024 12:32PM $0.058 $0.065 $0.061 risen by 12.07%
$13 Proposed issue of securities - ATX 16 Apr 2024 10:08AM $0.085 $0.065 $0.061 fallen by 23.53%
$13 Entitlement Offer Cleansing Statement 16 Apr 2024 10:08AM $0.085 $0.065 $0.061 fallen by 23.53%
$13 Rights Issue Investor Slide Deck 16 Apr 2024 10:08AM $0.085 $0.065 $0.061 fallen by 23.53%
$13 Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27 16 Apr 2024 10:07AM $0.085 $0.065 $0.061 fallen by 23.53%
$13 Trading Halt 12 Apr 2024 9:47AM $0.085 $0.065 $0.061 fallen by 23.53%
$13 AACR Conference Presentation 10 Apr 2024 8:22AM $0.078 $0.065 $0.061 fallen by 16.67%
$13 Update on ACCENT Trial in Pancreatic Cancer 27 Mar 2024 8:56AM $0.075 $0.065 $0.061 fallen by 13.33%
$13 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2024 12:33PM $0.081 $0.065 $0.061 fallen by 19.75%
$13 FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US 18 Jan 2024 9:42AM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Trading Halt 17 Jan 2024 2:26PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Pause in Trading 17 Jan 2024 2:17PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Amplia Reports First Patient Dosing In Phase 2a Accent Trial 17 Jan 2024 8:16AM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Change of Director's Interest Notice - Dr Warwick Tong 2 Jan 2024 12:48PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Change of Director's Interest Notice - Dr Chris Burns 2 Jan 2024 12:46PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Change of Director's Interest Notice - Dr Robert Peach 2 Jan 2024 12:42PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Change of Director's Interest Notice - Jane Bell 2 Jan 2024 12:41PM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Notification of cessation of securities - ATX 2 Jan 2024 11:41AM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Application for quotation of securities - ATX 2 Jan 2024 11:38AM $0.080 $0.065 $0.061 fallen by 18.75%
$13 Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea 4 Dec 2023 8:45AM $0.073 $0.065 $0.061 fallen by 10.96%
$13 Appendix 4D and Financial Report Half Year ended 30 Sep 23 21 Nov 2023 9:37AM $0.075 $0.065 $0.061 fallen by 13.33%
$13 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2023 10:41AM $0.083 $0.065 $0.061 fallen by 21.69%
$13 Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer 30 Oct 2023 8:17AM $0.083 $0.065 $0.061 fallen by 21.69%
$13 Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million 19 Oct 2023 8:15AM $0.083 $0.065 $0.061 fallen by 21.69%
$13 AACR Ovarian Cancer Conference Presentation 9 Oct 2023 8:55AM $0.088 $0.065 $0.061 fallen by 26.14%

1 - 25 of 345 results

Page 1 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.